West Pharmaceutical Services, Inc. Common Stock (WST)

NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against West Pharmaceutical Services, Inc. (“West” or the “Company”) (NYSE: WST).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against West Pharmaceutical Services, Inc. (“West Pharmaceutical” or the “Company”) (NYSE:WST) in the United States District Court for the Eastern District of Pennsylvania on behalf of all persons and entities who purchased or otherwise acquired West Pharmaceutical securities between February 16, 2023, and February 12, 2025, both dates inclusive (the “Class Period”). Investors have until July 7, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of West Pharmaceutical Services, Inc. (“West” or the “Company”) (NYSE: WST) investors concerning the Company’s possible violations of the federal securities laws.

Law Offices of Howard G. Smith announces an investigation on behalf of West Pharmaceutical Services, Inc. (“West” or the “Company”) (NYSE: WST) investors concerning the Company’s possible violations of federal securities laws.

The Law Offices of Frank R. Cruz announces an investigation of West Pharmaceutical Services, Inc. (“West” or the “Company”) (NYSE: WST) on behalf of investors concerning the Company’s possible violations of federal securities laws.

PHILADELPHIA, May 07, 2025 (GLOBE NEWSWIRE) --

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of West Pharmaceutical Services, Inc. (NYSE: WST) common stock between February 16, 2023 and February 12, 2025, inclusive (the “Class Period”), have until July 7, 2025 to seek appointment as lead plaintiff of the West Pharmaceutical class action lawsuit. Captioned New England Teamsters Pension Fund v. West Pharmaceutical Services, Inc., No. 25-cv-02285 (E.D. Pa.), the West Pharmaceutical class action lawsuit charges West Pharmaceutical and certain of West Pharmaceutical’s current and former top executives with violations of the Securities Exchange Act of 1934.

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against West Pharmaceutical Services, Inc. (“West” or “the Company”) (NYSE: WST) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against West Pharmaceutical Services, Inc. (“West” or the “Company”) (NYSE: WST) and reminds investors of the July 7, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Labaton Keller Sucharow LLP (“Labaton”) announces that, on May 5, 2025, it filed a securities class action lawsuit (the “Complaint”) on behalf of its client the New England Teamsters Pension Fund (“New England Teamsters”) against West Pharmaceutical Services, Inc. (“West” or the “Company”) (NYSE: WST) and certain West executives (collectively, “Defendants”). The action, which is captioned New England Teamsters Pension Fund v. West Pharmaceutical Services, Inc., No. 25-cv-02285 (E.D. Pa.) asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and U.S. Securities and Exchange Commission Rule 10b-5 promulgated thereunder, on behalf of all persons and entities that purchased or otherwise acquired West common stock between February 16, 2023 and February 12, 2025, inclusive (the “Class Period”).

Dividend Champions that have payout ratios below 20%, like these three stocks, can be an incredibly compelling choice for buy-and-hold dividend investors.

CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board.

EQNX::TICKER_START (NASDAQ:STSS),(NYSE:STVN),(NYSE:WST),(NYSE:BDX),(NYSE:PFE) EQNX::TICKER_END

Shares of West Pharmaceutical Services, Inc. (NYSE: WST) traded at a new 52-week high today and are currently trading at $395.02. So far today, approximately 202.24k shares have been exchanged, as compared to an average 30-day volume of 391.02k shares.

Analysts are forecasting a positive return for the S&P 500, and back-to-back downside years are rare. But weakening earnings could put a dent in returns.

Among the many industry sectors to invest in, healthcare can be one of the most stable, especially regarding the dividend yield.